Raymond James Downgrades IMS Health (RX) to Outperform
More News related to RX
- IMS to Present at J.P. Morgan Healthcare Conference on January 12 at 2:30 p.m. PST
- New Report Highlights Dramatic Change in U.S. Drug Spending Trends, Policy Implications
- IMS Health Reports Annual Global Generics Prescription Sales Growth of 3.6 Percent, to $78 Billion
- BioSyent Releases Financial Results-Third Quarter 2008
- BioSyent Releases Financial Results-Third Quarter 2008
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
Raymond James downgrades IMS Health (NYSE: RX) from Strong Buy to Outperform.
IMS Health Incorporated provides information, analytics, and consulting services to the pharmaceutical and healthcare industries worldwide.
Related Categories
DowngradesStocks Mentioned
-0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
